PaxMedica Inc. PXMD Archives

TuesdayJan 14, 2025 8:45 am

QualityStocksNewsBreaks – PaxMedica Inc. (PXMD) Secures Patent Approval in China for Autism Treatment

PaxMedica (OTC: PXMD), a clinical-stage biopharmaceutical company focused on neurological disorders, has received a Notification to Grant Patent Right for its Chinese invention patent application (No: 2020800553323). The patent covers compositions and methods for treating cognitive, social, or behavioral disabilities and neurodevelopmental disorders, including autism, using a novel intranasal suramin formulation. CEO Howard Weisman highlighted this as a historic milestone, marking the first intellectual property protection for suramin in over a century. PaxMedica plans to pursue similar protections in additional jurisdictions, including the United States. To view the full press release, visit https://ibn.fm/sn3b4 About PaxMedica Inc. PaxMedica is a forward-looking,…

TuesdayAug 27, 2024 10:54 am

QualityStocksNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Provides Update on Its Response to Extraordinary Request to Provide PAX-101 to Malawi

PaxMedica (NASDAQ: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced that the first patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense (“HAT”) in Malawi had been treated with PAX-101, an intravenous form of Suramin. The announcement noted that the Malawi Ministry of Health has informed PaxMedica that, following the treatment, the patient is recovering at home. The Rhodesiense strain of HAT is nearly 100% fatal if not treated promptly, and Suramin is considered the standard of care in Malawi and many East African countries. “The first use…

ThursdayAug 22, 2024 2:34 pm

QualityStocksNewsBreaks – PaxMedica Inc. (PXMD) Committed to Global Health, Potential Positive Impact of PAX-101

PaxMedica (OTC: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration for suramin to treat Human African Trypanosomiasis (“HAT”). “In April 2024, PaxMedica underscored its commitment to global health by responding to an urgent request from Malawi for an emergency release of suramin, demonstrating its dedication to advancing healthcare solutions. PaxMedica will have a crucial Type C meeting with the FDA, pivotal to the progress of PAX-101, its leading drug candidate for autism treatment, within the regulatory framework… This meeting is a significant event…

ThursdayJul 25, 2024 9:00 am

PaxMedica Inc. (NASDAQ: PXMD) Developing Treatments for Underserved Neurological Disorders

PaxMedica is preparing to submit a New Drug Application to the U.S. Food and Drug Administration for suramin to treat Human African Trypanosomiasis On June 27th, PaxMedica will have a Type C meeting with the FDA, pivotal for the progress of PAX-101, their leading drug candidate for autism treatment, within the regulatory framework The outcomes of this FDA meeting are crucial, representing a key moment for PaxMedica to demonstrate the therapeutic potential and public health benefits of PAX-101 The global ASD therapeutics market is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, driven by increasing…

MondayJul 01, 2024 2:30 pm

QualityStocksNewsBreaks – Golden Triangle Ventures Inc.’s (GTVH) Lavish Moves to Become Staple in the Entertainment Industry

Golden Triangle Ventures’ (OTC: GTVH) Lavish Entertainment embodies GTVH’s focus on vertical integration to cut costs and maximize margins, as evidenced by its recently released four-pillar business model. “According to GTVH, this strategic framework provides an essential piece of Lavish’s mission to create an industry leading entertainment business. The company’s new model includes key foundational elements – logistics, staffing, equipment and production – that were carefully identified and organized to complement each other and ensure seamless operations across all facets of the company. With its new business model as a backdrop, Lavish Entertainment plans to develop and acquire operations in…

MondayJul 01, 2024 1:44 pm

QualityStocksNewsBreaks – PaxMedica Inc. (PXMD) Intensifying Efforts to Achieve Significant Program Milestones

PaxMedica (OTC: PXMD), a biopharmaceutical company specializing in neurological disorders, is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for using suramin to treat Human African Trypanosomiasis (“HAT”), a well-established treatment in East Africa for nearly a century. A recent article discussed PaxMedica gearing up for a significant Type C meeting it had with the FDA, which “is critical for the advancement of PAX-101, the company’s leading drug candidate for treating autism, as it progresses through the regulatory framework… For PaxMedica, this Type C meeting is a strategic opportunity to engage with…

ThursdayJun 13, 2024 1:20 pm

QualityStocksNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Marks Major Milestone in Preparations for NDA Submission, Global Suramin Supply

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, recently completed its three registration/validation batches of PAX-101, an IV formulation of suramin. “This accomplishment marks a significant step toward submitting a New Drug Application (‘NDA’) to the U.S. Food and Drug Administration (‘FDA’) in the fourth quarter of 2024. This step paves the way for potential commercial availability in the U.S. of suramin, the sole form for treating stage 1 Human African Trypanosomiasis (‘HAT’) caused by Trypanosoma brucei rhodesiense. This disease, fatal and neglected, represents a critical healthcare challenge,” a recent article reads. “This completion of…

WednesdayMay 29, 2024 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) Shares Corporate Update and Commitment to Advancing Therapies for Neurological Disorders, Prepares for Key Engagements with the FDA

PaxMedica is preparing to submit a New Drug Application to the U.S. Food and Drug Administration later this year for using suramin to treat Human African Trypanosomiasis PaxMedica is currently preparing for an associated and very important Type C meeting with the FDA scheduled for June 27th Type C meetings are designated by the FDA to address specific issues in drug development, such as clinical trial design, data requirements, or other scientific matters not covered by Type A or Type B meetings PaxMedica (NASDAQ: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, recently shared corporate updates regarding its continued…

FridayMay 24, 2024 9:00 am

PaxMedica Inc. (NASDAQ: PXMD) Seeking to Qualify for Neglected Tropical Disease Priority Review Voucher Program in Wake of Malawi Major Sleeping Sickness Crisis

PaxMedica has received an urgent plea from the Ministry of Health of Malawi for emergency access to IV suramin to prevent a potential humanitarian crisis due to dwindling supplies of essential drugs used to save lives in the region PaxMedica has previously concluded a Type B meeting with the FDA in preparation for the NDA submission, focusing on the use of PAX-101 in treating the rare and fatal trypanosomal infection, Trypanosoma brucei rhodesiense, transmitted by tsetse flies PaxMedica also aims to potentially qualify for a Priority Review Voucher under the Neglected Tropical Disease Priority Review Voucher Program, which could provide…

WednesdayMay 22, 2024 2:51 pm

QualityStocksNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Ensuring Access to Life-Saving Treatments

PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, recently took swift action to address a pressing medical situation unfolding in Malawi, East Africa. “The Ministry of Health (‘MOH’) of Malawi has issued a plea for access to IV suramin, a vital medication in combating the life-threatening sleeping sickness crisis affecting the region. PaxMedica responded to this call for help by committing to provide emergency access to its recently completed registration batches of PAX-101, an IV form of suramin. This decision underscores PaxMedica’s dedication to mitigating the devastating impact of sleeping sickness and ensuring access to…

Site Search

Company Search

Tag: PaxMedica Inc. PXMD